Bench to Bedside: Unlocking the promise of radioligand therapy for Australian patients
Tracks
Track 1
| Wednesday, October 30, 2024 |
| 4:05 PM - 4:50 PM |
Overview
Sponsored by: NOVARTIS
Details
Australia is well placed to embrace and deliver on the promise of precision medicine and propel radioligand therapy from bench to bedside. There is significant opportunity for Australia to build on its global leadership in radioligand therapy research and development, by stewarding the translation of research to broad and equitable patient access while building a thriving nuclear medicine industry. To do so will require governments, industry, and academia to work collaboratively to develop a robust ecosystem that can capitalise on the health and economic potential of radioligand therapies, the next frontier in precision oncology
Speaker
Arthur Alston
Medical Head, Solid Tumours and Radioligand Therapies
Novartis Australia
Panellist
Renae Beardmore
Managing Director
Evohealth
Panellist
Meredith Cummins
Chief Executive Officer, Neuroendocrine Cancer Australia Colleen Jen, Deputy Director General, Clinical Planning and Service Strategy
Queensland Department of Health
Panellist
Professor Michael Hofman
Director, Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC)
Melbourne's Peter MacCallum Cancer Centre
Panellist
Colleen Jen
Deputy Director General
Queensland Department of Health
Panellist
Deanna Mill
Advisor
Evohealth
Chair
Professor Kris Thurecht
Acting Deputy Director & Group Leader, Centre for Advanced Imaging
University of Queensland
Panellist
Matt Zeller
Country President
Novartis Australia & New Zealand
Panellist
